MYTO Therapeutics
Dedicated to bringing treatments for diseases associated with mitochondrial dysfunction including Leigh's, LHON and Freidreich's Ataxia.
MYTO Therapeutics
Dedicated to bringing treatments for diseases associated with mitochondrial dysfunction.
Current Therapeutic Focus
Leigh’s Syndrome
Leigh’s Syndrome is a progressive neurometabolic disorder that can cause deterioration of the central nervous system, including the brain, spinal cord, and optic nerve.
LHON
Leber’s Hereditary Optic Neuropathy (LHON) is an inherited mitochondrial disease, as it is caused by a genetic mutation (variance) in the mitochondria that leads to sudden vision loss.
Friedreich's Ataxia
Friedreich's Ataxia (also called FA) is a rare inherited disease caused by a defect (mutation) in a gene labeled FXN, which leads to progressive nervous system damage and movement problems.
APPROACH
Myto’s approach is to identify and develop novel therapeutics to improve mitochondrial function.
MYT-109, the lead development candidate, shows improved mitochondrial function and efficacy in animal models of mitochondrial dysfunction of Leigh’s Syndrome, Leber’s Hereditary Optic Neuropathy & Friedreich’s Ataxia.
